This study is in progress, not accepting new patients
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
a study on Anemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- Links
- www.aihastudy.com
- ID
- NCT02612558
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated